BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 36198538)

  • 1. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
    Kumar A; Fraz MA; Usman M; Malik SU; Ijaz A; Durer C; Durer S; Tariq MJ; Khan AY; Qureshi A; Faridi W; Nasar A; Anwer F
    Curr Treat Options Oncol; 2018 Sep; 19(10):50. PubMed ID: 30173370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic developments and advances in B-cell lymphoma].
    Miyazaki K
    Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
    Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
    J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
    N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
    Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
    J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
    Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
    Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
    Lu Q; Huang H; Tang S; Wang Y; Yang DH
    Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
    Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
    Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
    Yu M; Zhang Q; Xu S; Yin T; Li F
    Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
    Di M; Huntington SF; Olszewski AJ
    Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in DLBCL: are we past the cell of origin?
    Goldfinger M; Cooper DL
    Clin Adv Hematol Oncol; 2021 May; 19(5):320-325. PubMed ID: 33989279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
    Malecek MK; Watkins MP; Bartlett NL
    Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
    Belada D; Kopeckova K; Bergua Burgues JM; Stevens D; André M; Persona EP; Pichler P; Staber PB; Trneny M; Duell J; Waldron-Lynch M; Wagner S; Mukhopadhyay A; Dirnberger-Hertweck M; Burke JM; Nowakowski GS
    Blood; 2023 Oct; 142(16):1348-1358. PubMed ID: 37369099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.